[{"id":"1a1995ad-1100-4dcd-ab6d-59a84e130062","acronym":"","url":"https://clinicaltrials.gov/study/NCT03641755","created_at":"2021-01-18T17:52:39.950Z","updated_at":"2025-02-25T15:07:53.071Z","phase":"Phase 1","brief_title":"Olaparib + Sapacitabine in BRCA Mutant Breast Cancer","source_id_and_acronym":"NCT03641755","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • PGR positive","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • sapacitabine (CYC682)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-09-19"},{"id":"c888a839-4434-4bf4-97af-0865b3e560f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00999401","created_at":"2021-01-18T03:54:26.432Z","updated_at":"2024-07-02T16:36:19.263Z","phase":"Phase 1","brief_title":"A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00999401","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapacitabine (CYC682) • seliciclib (CYC202)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 07/16/2019","primary_completion_date":" 07/16/2019","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2021-12-22"}]